Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin Mitigates WMH-Related Cognitive Impairment by Reducing VCAM-1
NCT07128212Completed
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of atorvastatin in Ischemic leukoencephalopathy (IL) and Cerebral Small Vessel Disease (CSVD) (3 arms), sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoint: Vascular Cell Adhesion Molecule-1 levels at 2 years. Started Jan 2021; status: completed.
02
Drugs
atorvastatin
03
Conditions
Ischemic leukoencephalopathy (IL)Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on NCT07128212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128212.